ENOS MedShop ENOS Labs

Educational resource · All compounds discussed are for laboratory research use only · Not for human or veterinary use

Clinical tracker

Retatrutide tracker

Retatrutide is an investigational GIP, GLP-1 and glucagon triple receptor agonist in development by Eli Lilly and Company. This timeline cites only public company releases, SEC filings and trial registries.

ENOS Med is not affiliated with or endorsed by Eli Lilly and Company. Retatrutide is an investigational compound not approved by the FDA.

  1. TRIUMPH-2 detailed results presented

    Detailed Phase 3 results in adults with obesity and type 2 diabetes presented at EASD and published in The Lancet.

    Lilly press release

  2. TRIUMPH-2 and TRIUMPH-3 topline results

    Both pivotal trials met their primary endpoints. Lilly stated plans to submit a BLA to the FDA in Q1 2027.

    Lilly press release

  3. Additional Phase 3 data at ADA Scientific Sessions

    Further TRIUMPH-1 and TRANSCEND-T2D-1 results presented, including knee osteoarthritis and obstructive sleep apnea endpoints.

    Lilly press release

  4. TRIUMPH-1 topline results

    Pivotal Phase 3 obesity trial met primary and key secondary endpoints.

    Lilly press release

  5. TRANSCEND-T2D-1 topline results

    First Phase 3 trial in type 2 diabetes met primary and all key secondary endpoints versus placebo.

    Lilly press release

  6. TRIUMPH-4: first successful Phase 3 trial

    Phase 3 trial in obesity with knee osteoarthritis met all primary and key secondary endpoints.

    Lilly press release

Primary sources

Published research

Sourcing peptides for your lab?

Browse research-grade peptides with documentation at ENOS Labs USA. For research use only.

Visit ENOS Labs